BAFNAPHARM - Board Meeting Intimation for Board Meeting To Consider The Unaudited Results For The Quarter Ended 30.06.2022

BAFNAPHARM - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report

BAFNAPHARM - Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations, 2015)

BAFNAPHARM - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

BAFNAPHARM - Announcement under Regulation 30 (LODR)-Newspaper Publication

BAFNAPHARM - Reg. 34 (1) Annual Report.

BAFNAPHARM - Intimation Of Annual General Meeting And Book Closure Under Regulation 42 Of The Securities And Exchange Board Of India #Part1

BAFNAPHARM - Statement Of Investor Complaints For The Quarter Ended March 2022

BAFNAPHARM - Compliance Certificate For The Half Year Ended 31St March 2022

BAFNAPHARM - Format of Initial Disclosure to be made by an entity identified as a Large Corporate

BAFNAPHARM - Closure of Trading Window

BAFNAPHARM - Appointment of Company Secretary and Compliance Officer

BAFNAPHARM - Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer

BAFNAPHARM - Board Meeting Outcome for Outcome Of Board Meeting Held On 21St March 2022

BAFNAPHARM - Board Meeting Intimation for To Consider Resignation And Appointment Of Company Secretary (KMP) Of The Company And Any #Part1

BAFNAPHARM - Proposed Sale Of Equity Shares Of Bafna Pharmaceuticals Limited By SRJR Life Sciences LLP, Through Open Market Sale For #Part1

Bafna Pharmaceuticals Q3FY22 net profit at Rs. 1.70 crore #BafnaPharmaceuticals #Q3FY22 #9MFY22 #ResultUpdate